|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921149B1
(ru)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921148B1
(ru)
|
1970-12-28 |
1974-05-30 |
|
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
WO1992000970A1
(fr)
|
1990-07-03 |
1992-01-23 |
Mitsui Petrochemical Industries, Limited |
Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose
|
|
CA2190973C
(en)
|
1995-04-13 |
2001-06-19 |
Yasuo Konno |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
ES2213286T3
(es)
|
1997-07-24 |
2004-08-16 |
Zenyaku Kogyo Kabushiki Kaisha |
Compuestos heterociclicos y agente antitumoral que los contiene como ingredientes activos.
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
ES2193607T3
(es)
|
1998-01-16 |
2003-11-01 |
Hoffmann La Roche |
Derivados de benzosulfona .
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
WO1999065897A1
(en)
|
1998-06-19 |
1999-12-23 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
EP1144390A2
(en)
|
1999-01-22 |
2001-10-17 |
Amgen Inc., |
Kinase inhibitors
|
|
EP1206260A4
(en)
|
1999-06-30 |
2002-10-30 |
Merck & Co Inc |
SRC-KINASE INHIBITING COMPOUNDS
|
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
SIN KINASE INHIBITOR COMPOUNDS
|
|
CA2383546A1
(en)
|
1999-06-30 |
2001-01-04 |
William H. Parsons |
Src kinase inhibitor compounds
|
|
JP2003505384A
(ja)
|
1999-07-15 |
2003-02-12 |
ファーマコピーア，インコーポレーティッド |
ブラジキニンｂ１受容体アンタゴニスト
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
MXPA02007957A
(es)
|
2000-02-17 |
2002-11-29 |
Amgen Inc |
Inhibidores de cinasas.
|
|
NZ521068A
(en)
|
2000-03-29 |
2005-04-29 |
Cyclacel Ltd |
2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
|
|
AU5261001A
(en)
|
2000-04-27 |
2001-11-12 |
Imperial Cancer Research Technology Ltd |
Condensed heteroaryl derivatives
|
|
NZ522217A
(en)
|
2000-04-28 |
2004-04-30 |
Tanabe Seiyaku Co |
Cyclic compounds
|
|
WO2002000647A1
(en)
|
2000-06-23 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
|
KR100816769B1
(ko)
|
2000-09-06 |
2008-03-26 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
글리코겐 합성효소 키나아제 3의 억제제
|
|
ATE326458T1
(de)
|
2000-09-15 |
2006-06-15 |
Vertex Pharma |
Pyrazolverbindungen als protein-kinasehemmer
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
DK1353916T3
(da)
|
2000-12-21 |
2007-01-29 |
Vertex Pharma |
Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
AU2002258400A1
(en)
|
2001-02-16 |
2002-08-28 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
WO2002102313A2
(en)
|
2001-06-19 |
2002-12-27 |
Bristol-Myers Squibb Company |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
AU2003220300A1
(en)
|
2002-03-15 |
2003-09-29 |
Binch, Hayley |
Compositions useful as inhibitors of protein kinases
|
|
ATE433973T1
(de)
|
2002-03-15 |
2009-07-15 |
Vertex Pharma |
Azolylaminoazine als inhibitoren von proteinkinasen
|
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
AU2003245669A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain aromatic monocycles as kinase modulators
|
|
US7405221B2
(en)
|
2002-09-27 |
2008-07-29 |
Merck & Co., Inc. |
Substituted pyrimidines
|
|
EP1562605A4
(en)
|
2002-10-08 |
2006-07-12 |
Massachusetts Inst Technology |
COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
PL377821A1
(pl)
|
2002-11-21 |
2006-02-20 |
Chiron Corporation |
2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
|
|
CA2514733A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
WO2004084824A2
(en)
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc. |
Biaryl substituted 6-membered heterocyles as sodium channel blockers
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
US7763627B2
(en)
|
2003-04-09 |
2010-07-27 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
WO2005009977A1
(en)
|
2003-07-15 |
2005-02-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
|
|
CA2531619A1
(en)
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
JP2007532669A
(ja)
|
2004-04-13 |
2007-11-15 |
イカジェン インコーポレイテッド |
カリウムイオンチャネル調節剤としての多環式ピリミジン
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
AU2005312048B2
(en)
*
|
2004-11-30 |
2012-08-02 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
|
US20080045525A1
(en)
|
2004-12-13 |
2008-02-21 |
Rajagopal Bakthavatchalam |
Piperazinyl-Pyridine Analogues
|
|
EP1824839A2
(en)
|
2004-12-13 |
2007-08-29 |
Neurogen Corporation |
Substituted biaryl analogues
|
|
PL1836169T3
(pl)
|
2004-12-28 |
2012-07-31 |
Kinex Pharmaceuticals Llc |
Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
|
|
AU2006206246A1
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
JP2008531537A
(ja)
|
2005-02-25 |
2008-08-14 |
クドス ファーマシューティカルズ リミテッド |
化合物
|
|
AR053712A1
(es)
|
2005-04-18 |
2007-05-16 |
Neurogen Corp |
Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
CA2635997A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
EP2012794B1
(en)
*
|
2006-04-13 |
2014-09-17 |
The Trustees of Columbia University in the City of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
TW200833342A
(en)
|
2006-12-28 |
2008-08-16 |
Basf Ag |
2-substituted pyrimidines I in therapy
|
|
KR20090108124A
(ko)
|
2007-02-06 |
2009-10-14 |
노파르티스 아게 |
Ｐｉ 3-키나제 억제제 및 그의 사용 방법
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
WO2009007748A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
AU2009221164B2
(en)
|
2008-03-05 |
2012-07-26 |
Novartis Ag |
Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
|
|
US20110020338A1
(en)
|
2008-03-26 |
2011-01-27 |
Carlos Garcia-Echeverria |
5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes
|
|
US20110053907A1
(en)
|
2008-03-27 |
2011-03-03 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
JP5277256B2
(ja)
|
2008-04-09 |
2013-08-28 |
田辺三菱製薬株式会社 |
ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
KR20110090911A
(ko)
|
2008-10-31 |
2011-08-10 |
노파르티스 아게 |
포스파티딜이노시톨-3-키나아제 (ｐｉ3ｋ) 억제제 및 ｍｔｏｒ 억제제의 조합물
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
US8513242B2
(en)
|
2008-12-12 |
2013-08-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
RU2535217C2
(ru)
|
2009-02-06 |
2014-12-10 |
Ниппон Синяку Ко., Лтд. |
Производные аминопиразина и лекарственные средства
|
|
JP6067226B2
(ja)
|
2009-03-13 |
2017-01-25 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
細胞増殖関連疾患のための方法および組成物
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
DK2432767T3
(da)
|
2009-05-19 |
2013-09-30 |
Dow Agrosciences Llc |
Forbindelser og fremgangsmåder til at kontrollere svampe
|
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
US8609676B2
(en)
|
2009-08-04 |
2013-12-17 |
Merck Sharp & Dohme, Corp. |
4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
BR112012008385A2
(pt)
|
2009-09-09 |
2019-09-24 |
Avila Therapeutics Inc |
inibidores de p13 cinase e uso dos mesmos.
|
|
JP5967827B2
(ja)
|
2009-12-09 |
2016-08-10 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
US20130109643A1
(en)
|
2010-05-10 |
2013-05-02 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
AU2011278998B2
(en)
|
2010-07-16 |
2016-06-09 |
Les Laboratoires Servier |
Therapeutically active compositions and their method of use
|
|
ES2699951T3
(es)
|
2010-10-01 |
2019-02-13 |
Novartis Ag |
Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
|
|
EP2629776B1
(en)
|
2010-10-18 |
2017-08-16 |
Cerenis Therapeutics Holding SA |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
RU2013141559A
(ru)
|
2011-02-11 |
2015-03-20 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Способ ингибирования клеток опухоли гамартомы
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
US20140213583A1
(en)
|
2011-09-01 |
2014-07-31 |
Novartis Ag |
PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone
|
|
CU24269B1
(es)
|
2011-09-27 |
2017-08-08 |
Novartis Ag |
3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
|
|
JP2014528446A
(ja)
|
2011-10-06 |
2014-10-27 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
１，３−置換アゼチジンｐｄｅ１０阻害剤
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
BR112014028420A2
(pt)
*
|
2012-05-16 |
2017-09-19 |
Novartis Ag |
regime de dosagem para um inibidor de quinase pi-3
|
|
EP2858631A1
(en)
|
2012-06-06 |
2015-04-15 |
Novartis AG |
Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
|
|
EP2885003B1
(en)
|
2012-08-16 |
2021-09-29 |
Novartis AG |
Combination of pi3k inhibitor and c-met inhibitor
|
|
CA2885471C
(en)
|
2012-10-23 |
2021-02-23 |
Dietmar Flubacher |
Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
EA028033B1
(ru)
|
2013-03-14 |
2017-09-29 |
Новартис Аг |
3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
|
|
CA2903176A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|